1. Home
  2. SNGX vs AIMD Comparison

SNGX vs AIMD Comparison

Compare SNGX & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • AIMD
  • Stock Information
  • Founded
  • SNGX 1987
  • AIMD 1984
  • Country
  • SNGX United States
  • AIMD United States
  • Employees
  • SNGX N/A
  • AIMD N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • AIMD Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNGX Health Care
  • AIMD Health Care
  • Exchange
  • SNGX Nasdaq
  • AIMD Nasdaq
  • Market Cap
  • SNGX 7.4M
  • AIMD 8.5M
  • IPO Year
  • SNGX 1987
  • AIMD N/A
  • Fundamental
  • Price
  • SNGX $2.39
  • AIMD $0.74
  • Analyst Decision
  • SNGX
  • AIMD
  • Analyst Count
  • SNGX 0
  • AIMD 0
  • Target Price
  • SNGX N/A
  • AIMD N/A
  • AVG Volume (30 Days)
  • SNGX 44.9K
  • AIMD 379.0K
  • Earning Date
  • SNGX 03-14-2025
  • AIMD 03-07-2025
  • Dividend Yield
  • SNGX N/A
  • AIMD N/A
  • EPS Growth
  • SNGX N/A
  • AIMD N/A
  • EPS
  • SNGX N/A
  • AIMD N/A
  • Revenue
  • SNGX $364,183.00
  • AIMD $40,633.00
  • Revenue This Year
  • SNGX N/A
  • AIMD N/A
  • Revenue Next Year
  • SNGX $76.64
  • AIMD N/A
  • P/E Ratio
  • SNGX N/A
  • AIMD N/A
  • Revenue Growth
  • SNGX N/A
  • AIMD N/A
  • 52 Week Low
  • SNGX $1.83
  • AIMD $0.40
  • 52 Week High
  • SNGX $14.88
  • AIMD $3.10
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 43.83
  • AIMD 59.44
  • Support Level
  • SNGX $2.25
  • AIMD $0.57
  • Resistance Level
  • SNGX $2.60
  • AIMD $0.77
  • Average True Range (ATR)
  • SNGX 0.15
  • AIMD 0.06
  • MACD
  • SNGX 0.03
  • AIMD -0.00
  • Stochastic Oscillator
  • SNGX 52.27
  • AIMD 68.48

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About AIMD Ainos Inc.

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

Share on Social Networks: